A rare HIV-associated hyaline vascular multicentric castleman disease with good early response to single-agent rituximab: A case from Tanzania

被引:0
作者
Mawalla, William Frank [1 ]
Tibursi, Antimon [1 ]
Mnango, Leah [2 ]
Nasser, Ahlam [1 ]
Saleh, Saida Salim [1 ]
Mmbaga, Lilian Gasper [1 ]
Chamba, Clara [1 ]
Schuh, Anna [1 ,4 ]
Meda, Collins [3 ]
机构
[1] Muhimbili Univ Hlth & Allied Sci, Dept Haematol & Blood Transfus, Dar Es Salaam, Tanzania
[2] Muhimbili Natl Hosp, Dept Pathol, Dar Es Salaam, Tanzania
[3] Muhimbili Natl Hosp, Dept Internal Med, Dar Es Salaam, Tanzania
[4] Univ Oxford, John Radcliffe Hosp, Oxford Univ Hosp NHS Trust, NIHR BRC Oxford Mol Diagnost Ctr, Oxford, England
来源
HUMAN PATHOLOGY REPORTS | 2022年 / 30卷
关键词
Keywords; HIV; Castleman's Disease; HHV-8; Multicentric Castleman Disease; Rituximab; LYMPH-NODE HYPERPLASIA; CRITERIA; PROTEIN; SERUM; IL-6;
D O I
10.1016/j.hpr.2022.300677
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background: Castleman's Disease (CD) is a diverse group of non-neoplastic lymphoproliferative disorders characterized by lymphoid endothelial and follicular hyperplasia. Human Immunodeficiency Virus (HIV)-associated Human Herpes Virus type-8 (HHV-8) CD is a form of CD affecting HIV-positive individuals with concomitant HHV-8 infection as the aetiological driver. While the prevalence of HIV and HHV-8 is high in Sub-Saharan Africa (SSA), there are however very few reported cases of CD from the region. This might reflect a high rate of misdiagnosis and under-reporting of HIV-associated HHV-8 CD in limited-resource settings. If diagnosed early and precisely, the HIV-associated HHV-8 CD can be successfully treated with chemotherapy and/or single-agent targeted therapy (rituximab), regimens that are increasingly becoming available. Case presentation: We highlight a rare case of HHV-8 associated Multicentric Castleman Disease (MCD) in an HIV- positive individual who presented with lymphadenopathy, haemolytic anaemia, monoclonal gammopathy and atypical hyaline vascular variant and showed good early response with single-agent rituximab. Conclusions: A high index of suspicion is needed to diagnose CD, especially in regions where infectious diseases are common and share clinicopathological features with malignant diseases. Early diagnosis is the key to appropriate management, with a potential cure for the disease.
引用
收藏
页数:6
相关论文
共 41 条
[1]   Brief communication: Rituximab in HIV-associated multicentric Castleman disease [J].
Bower, Mark ;
Powles, Tom ;
Williams, Sarah ;
Davis, Tom Newsom ;
Atkins, Mark ;
Montoto, Silvia ;
Orkin, Chloe ;
Webb, Andy ;
Fisher, Martin ;
Nelson, Mark ;
Gazzard, Brian ;
Stebbing, Justin ;
Kelleher, Peter .
ANNALS OF INTERNAL MEDICINE, 2007, 147 (12) :836-839
[2]   Clinical Features and Outcome in HIV-Associated Multicentric Castleman's Disease [J].
Bower, Mark ;
Newsom-Davis, Tom ;
Naresh, Kikkeri ;
Merchant, Shairoz ;
Lee, Belinda ;
Gazzard, Brian ;
Stebbing, Justin ;
Nelson, Mark .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18) :2481-2486
[3]   How I treat HIV-associated multicentric Castleman disease [J].
Bower, Mark .
BLOOD, 2010, 116 (22) :4415-4421
[4]   Multicentric Castleman's disease in human immunodeficiency virus infection: Two case reports [J].
Caroline Ribeiro Sales A. ;
De Souza Junior V.R. ;
Iglis De Oliveira M. ;
Azevedo Braga Albuquerque C. ;
De Barros Campelo Júnior E. ;
Sérgio Ramos De Araújo P. .
Journal of Medical Case Reports, 12 (1)
[5]  
CASTLEMAN B, 1956, CANCER-AM CANCER SOC, V9, P822, DOI 10.1002/1097-0142(195607/08)9:4<822::AID-CNCR2820090430>3.0.CO
[6]  
2-4
[7]   Immunological and Inflammatory Functions of the Interleukin-1 Family [J].
Dinarello, Charles A. .
ANNUAL REVIEW OF IMMUNOLOGY, 2009, 27 :519-550
[8]   Overview of Castleman disease [J].
Dispenzieri, Angela ;
Fajgenbaum, David C. .
BLOOD, 2020, 135 (16) :1353-1364
[9]   Kaposi sarcoma-associated herpesvirus infects monotypic (IgMλ) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders [J].
Du, MQ ;
Liu, HX ;
Diss, TC ;
Ye, HT ;
Hamoudi, RA ;
Dupin, N ;
Meignin, V ;
Oksenhendler, E ;
Boshoff, C ;
Isaacson, PG .
BLOOD, 2001, 97 (07) :2130-2136
[10]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247